{
  "id": 4750344,
  "title": "Mpm Bioventures 2018 sells $615,777 in Entrada Therapeutics stock",
  "url": "https://urgent.news/2026/09/01/mpm-bioventures-2018-sells-615-777-in-entrada-therapeutics-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-01T00:16:35.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/mpm-bioventures-2018-sells-615777-in-entrada-therapeutics-stock-93CH-4883393"
  },
  "original_language": "en",
  "account": "MPM BioVentures 2018 sold $615,777 worth of Entrada Therapeutics stock in a span of four days in late August 2026. The company, which owned 10% of the business, made multiple transactions involving different numbers of shares at varying prices. On August 27, they sold 38,922 shares at an average price of $7.2 per share. The following day, they sold 3,733 shares at $7.01 each, and on August 31, they closed the transactions with a sale of 44,259 shares at $6.99 per share. After all the sales, MPM BioVentures held roughly 4.23 million shares of the company. Analysts currently view the stock as potentially undervalued, with price targets ranging from $11 to $25. Despite the recent sales, the company's financials show it has more cash on hand than debt. MPM BioVentures is still the 10% owner and director of Entrada Therapeutics. Meanwhile, the company has received approval to increase the dose in its ELEVATE-45-201 study for Duchenne muscular dystrophy. This progress underscores the company's commitment to advancing its clinical pipeline.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Mpm Bioventures 2014 L.P. sells $615,777 of Entrada Therapeutics stock",
        "url": "https://urgent.news/2026/08/31/mpm-bioventures-2014-l-p-sells-615-777-of-entrada-therapeutics-stock",
        "published": "2026-08-31T23:01:15.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}